Upstream Bio Lead Drug Pivotal Trial Plan Follows Strong Phase 2 Data
The company reported a cash position of $341.5 million, expected to fund planned operations through 2027.
Open original sourceLoading market dashboard
The company reported a cash position of $341.5 million, expected to fund planned operations through 2027.
Open original source